Department of Pediatrics, Division of Cardiology, University of Tennessee Health Science Center, Le Bonheur Children's Hospital, Memphis, TN, USA.
Future Cardiol. 2024;20(9):459-470. doi: 10.1080/14796678.2024.2355057. Epub 2024 Sep 5.
The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions. Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023. The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications. The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.
Amplatzer Piccolo Occluder（APO）已获准用于体重 >700g 的婴儿动脉导管未闭（PDA）封堵，但也可用于治疗其他病变。回顾性分析 2022 年 1 月至 2023 年 6 月期间，APO 用于治疗除 PDA 以外其他病变的患儿。APO 用于 9 例患儿：3 例室间隔缺损，4 例冠状动脉瘘，1 例室壁假性动脉瘤，1 例 APO 位于先前放置的 Amplatzer 房间隔封堵器的开窗内。9 例患儿均成功封堵，无并发症。APO 是一种多功能装置，除了目前获准用于 PDA 封堵之外，还可用于治疗各种小儿小直径病变。
